Data updated: May 26, 2026
ASCOR (ascorbic acid)
Other
Approved 2017-10-02
ASCOR is indicated for the treatment of Scurvy; Vitamin C Deficiency.
Source: FDA Label • MCGUFF
1
Indication
--
Phase 3 Trials
8
Years on Market
Details
- Status
- Prescription
- First Approved
- 2017-10-02
- Routes
- INTRAVENOUS
- Dosage Forms
- SOLUTION
ASCOR Approval History
2018
2019
2020
2021
2022
2023
2024
2025
2026
Original
New Indication
New Form
Label Update
4 FDA actions from 2017 to 2024
Apr 2023 SUPPL
Mfg · Manufacturing (CMC)
What ASCOR Treats
2 indicationsASCOR is approved for 2 conditions since its original approval in 2017. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Scurvy
- Vitamin C Deficiency
Source: FDA Label
ASCOR Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
2
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to ASCOR
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
📋
Clinical Trial Registry
46 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT04138394 VICToRY | VICToRY | Ph 3 | suspended | VItamin C in Thermal injuRY: The VICToRY Trial |
| NCT04756063 PARTI | 2020-1153 A530900, SMPH/ANESTHESIOLOGY | Ph 4 | suspended | Parenteral Ascorbic Acid Repletion in TransplantatIon |
| NCT02905591 XACT-LUNG | 201712770 3P30CA086862, 5U01CA140206 | Ph 2 | active not recruiting | A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC |
| NCT05849129 AIVAA | 20220721-01H | Ph 2 | recruiting | Adjunctive Intravenous Ascorbic Acid for Advanced Non-Small Cell Lung Cancer |
| NCT02344355 | 201504786 | Ph 2 | active not recruiting | A Phase 2 Trial of High-Dose Ascorbate in Glioblastoma Multiforme |
| NCT01550510 results posted | 11D.459 JT 1548 | Ph 1, Ph 2 | terminated | Research Study of IV Vitamin C in Combination With Irinotecan vs Irinotecan Alone for Advanced Colorectal CA |
| NCT01555489 results posted | 11D.365 JT 2181 | Ph 2 | terminated | Assessing the Efficacy and Safety of IV Vitamin C in Combination With Standard Chemotherapy for Pancreatic Ca |
| NCT04046094 results posted | IIT-2019-IVC_CarboGem UL1TR002366 | Ph 1, Ph 2 | active not recruiting | Intravenous (IV) Vitamin C With Chemotherapy for Cisplatin Ineligible Bladder Cancer Patients |
| NCT04516681 | Vitamin C-GLUT3-2020 | Ph 3 | recruiting | Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer |
| NCT02420314 results posted | 201412760 3P30CA086862 | Ph 2 | completed | Pharmacological Ascorbate for Lung Cancer |
| NCT06421688 | YXLL-KY-2024(039) | Ph 2 | not yet recruiting | Effect of Vitamin C on Postoperative Pulmonary Complications After Intracranial Tumor Surgery |
| NCT06224881 | MS-362-2019 | Ph 4 | completed | Vitamin C Deficiency in Septic Shock |
| NCT02969681 Vitality | VitC001 | Ph 3 | completed | Vitamin C Intravenously With Chemotherapy in Advanced Colorectal Cancer |
| NCT03410030 AA NABPLAGEM | SU2C HRI NPG-002 | Ph 1, Ph 2 | completed | Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) |
| NCT02209636 results posted | CLNB-006-13F CX001030 | Ph 4 | completed | Phosphate Lowering in CKD Trial |
| NCT04354428 results posted | STUDY00009878 INV-017062 | Ph 2, Ph 3 | terminated | Treatment for COVID-19 in High-Risk Adult Outpatients |
| NCT03334409 results posted | ACCRU-GU-1703 NCI-2017-01998, ACCRU-GU-1703 | Ph 2 | terminated | Pazopanib Hydrochloride With or Without Ascorbic Acid in Treating Patients With Kidney Cancer That Is Metastatic or Cannot Be Removed by Surgery |
| NCT04328961 results posted | STUDY00009750 INV-016204 | Ph 2, Ph 3 | completed | Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP) |
| NCT03422159 ORANGES results posted | 17-004 | Ph 2 | completed | Metabolic Resuscitation Using Ascorbic Acid, Thiamine, and Glucocorticoids in Sepsis. |
| NCT03397173 | CASE1917 | Ph 2 | completed | TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid |
| NCT03123107 | 2016-0463 | Ph 1 | completed | Vitamin C in Cardiac Surgery Patients |
| NCT02734147 results posted | 603204 | Ph 2 | terminated | High Dose Intravenous Ascorbic Acid in Severe Sepsis |
| NCT04135378 | KufaU2 | Ph 4 | completed | Effect of Low Doses of Vitamin C on Salivary Cortisol , Heart Rate , Blood Pressure During Group Presentation |
| NCT02106975 CITRIS-ALI results posted | HM20000917 1UM1HL116885-01 | Ph 2 | completed | Vitamin C Infusion for Treatment in Sepsis Induced Acute Lung Injury |
| NCT03226431 ARINA-1 | Pro00080819 | Ph 1 | completed | Use of ARINA-1 in an Intermediate Size Patient Population of Bilateral Lung Transplant Patients With CLAD Grade 0 |
| NCT02762331 results posted | HM20000539 | Ph 1 | terminated | High Dose Vitamin C in Cardiac Surgery Patients |
| NCT03697239 | 181045 | Ph 1, Ph 2 | withdrawn | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer |
| NCT03797443 | PAN-VITC | Ph 1, Ph 2 | withdrawn | High Dose Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer |
| NCT03908333 | PRO00034648 | Ph 1, Ph 2 | withdrawn | High Dose Ascorbic Acid and Nanoparticle Paclitaxel Protein Bound and Cisplatin and Gemcitabine (AA NABPLAGEM) in Patients Who Have Metastatic Pancreatic Cancer |
| NCT02868151 | ECR/227/INSP/AP/2014 | Ph 2, Ph 3 | completed | Effect of Oral Vitamin C in Assessing the Severity of Oral Mucositis in Chemoradiation of Head and Neck Cancers |
| NCT03066115 | 2016-1014 | Ph 1 | withdrawn | Impact of NOS, COX, and ROS Inhibition on Cerebral Blood Flow Regulation |
| NCT00953212 results posted | MMC-3514 | Ph 3 | completed | Prophylaxis to Reduce Postoperative Atrial Fibrillation in Cardiac Surgery |
| NCT02793648 | PI-0290-2012 | Ph 2 | completed | Effectiveness of Ascorbic Acid and Tocopherol for Depression in Elderly. |
| NCT01434121 results posted | HM12903 | Ph 1, Ph 2 | completed | Ascorbic Acid (Vitamin C) Infusion in Human Sepsis |
| NCT01715597 | SNUBH_GO_016 | Ph 3 | completed | Study on the Effect of Intravenous Ascorbic Acid on Intraoperative Blood Loss in Women With Uterine Myoma |
| NCT02455180 | NL50578.029.14 2014-003680-38 | Ph 4 | completed | Pharmacokinetics of Two Different High-dose Regimens of Intravenous Vitamin C in Critically Ill Patients |
| NCT02521077 | MZ2015010 | Ph 2 | withdrawn | Intravenous Ascorbic Acid in Women Receiving Adjuvant or Neo-Adjuvant Chemotherapy for Early Stage Breast Cancer |
| NCT01587963 VitC results posted | 0220100048 | Ph 2 | terminated | High Dose Vitamin C in the Critically Ill Patient |
| NCT02602483 | JAN12006-01 | Ph 1, Ph 2 | completed | Exploratory Study To Assess the Efficacy and Safety of a Triple Combination for Acute Pain Treatment in Patients With Temporomandibular Joint Disorders (TMJD). |
| NCT02745873 LDVC | LDVC | Ph 2, Ph 3 | completed | Lead Detoxifying Effects of Ascorbic Acid Among School Going Adolescents of Karachi- A Cluster Randomized Control Trial |
| NCT02606773 | NVP-14C | Ph 1 | completed | "Novo C Plus" Vitamin C Containing Dietary Supplement Bioavailability in Healthy Subjects |
| NCT01332578 results posted | C7591227 | Ph 4 | completed | A Comparison of Solid and Soluble Forms of Cold and Influenza Remedies |
| NCT01580683 | WU0811SB | Ph 3 | withdrawn | Vitamin C and Atrial Fibrillation After Cardiac Surgery |
| NCT01322061 | ANES.GK.06 AUBMC | Ph 4 | completed | Vitamin C Efficacy in Reducing Post Operative Pain |
| NCT00519337 AFIST | WHIT002743HE | Ph 4 | completed | Impact of Ascorbic Acid on Post-Cardiothoracic Surgery Inflammation |
| NCT01270152 | 0925-0586 | Ph 2 | completed | Determining the Safe Dosage of Ascorbic Acid Used in the Treatment of Occluded Totally Implanted Central Venous Catheter |
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
|
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ASCOR FDA Label Details
Indications & Usage
FDA Label (PDF)ASCOR is indicated for the treatment of Scurvy; Vitamin C Deficiency.
Track ASCOR with TheraRadar Pro
Watchlist alerts, full database access, CSV exports across 14,000+ drugs.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.